WEBULL
News
ACOG
6.50
-1.52%
-0.10
Weekly Report: what happened at ACOG last week (1222-1226)?
Weekly Report · 12/29/2025 10:22
Weekly Report: what happened at ACOG last week (1215-1219)?
Weekly Report · 12/22/2025 10:22
Alpha Cognition Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 12/19/2025 13:09
HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $18 Price Target
Benzinga · 12/19/2025 12:59
Alpha Cognition: Undervalued ZUNVEYL Growth Story Supports Reiterated Buy Rating and $18 Target
TipRanks · 12/19/2025 11:25
Weekly Report: what happened at ACOG last week (1208-1212)?
Weekly Report · 12/15/2025 10:30
Weekly Report: what happened at ACOG last week (1201-1205)?
Weekly Report · 12/08/2025 10:28
Alpha Cognition CEO Joins Titan Partners Virtual Fireside Chat
Reuters · 12/01/2025 22:51
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners
Barchart · 12/01/2025 16:51
Weekly Report: what happened at ACOG last week (1124-1128)?
Weekly Report · 12/01/2025 10:23
Analysts Offer Insights on Healthcare Companies: Co-Diagnostics (CODX), Stevanato Group (STVN) and Alpha Cognition Inc (ACOG)
TipRanks · 11/24/2025 11:30
Weekly Report: what happened at ACOG last week (1117-1121)?
Weekly Report · 11/24/2025 10:29
Weekly Report: what happened at ACOG last week (1110-1114)?
Weekly Report · 11/17/2025 10:29
Alpha Cognition’s Earnings Call: Strong Sales and Strategic Growth
TipRanks · 11/15/2025 00:35
Alpha Cognition Reports $2.8 Million Revenue and Expanding ZUNVEYL Adoption in Q3 2025
Reuters · 11/14/2025 14:47
Alpha Cognition Inc. Reports Q3 2025 Earnings and Strategic Progress
TipRanks · 11/14/2025 04:43
Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/13/2025 23:40
Alpha Cognition reports Q3 results
Seeking Alpha · 11/13/2025 21:22
Alpha Cognition Q3 Sales $2.300M Beat $2.033M Estimate
Benzinga · 11/13/2025 21:04
*Alpha Cognition 3Q Rev $2.8M >ACOG
Dow Jones · 11/13/2025 21:01
More
Webull provides a variety of real-time ACOG stock news. You can receive the latest news about Alpha Cognition through multiple platforms. This information may help you make smarter investment decisions.
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.